Toronto-based psychedelic therapy company Reunion Neuroscience has entered a partnership with Fluence, a company providing training for psychedelic therapy, to conduct a Phase II clinical trial of Reunion's lead asset, RE104, for treating postpartum depression (PPD).

Under the terms of the partnership, Fluence will support the generation of training material, hosting the training program, and training study monitors. RE104 is a patented prodrug of the 4-OH-DiPT compound, being explored by Reunion for treating mental health disorders, starting with PPD.

Analyst QuickTake: Over the years, Fluence has built partnerships to offer certification for mental health practitioners in psychedelic therapy and integration. Notable collaborations include 1) Psyence , to conduct a Phase IIb clinical trial investigating psilocybin-assisted psychotherapy for cancer patients with adjustment disorder (April 2024), 2) Cybin , to expand the EMBARK training program for the CYB003 trial (September 2023), and 3) Tryp Therapeutics , to support a Phase IIa clinical trial and design psychotherapy protocols (May 2021).